JP2022074265A - Reagent for immunonephelometry and kit therefor - Google Patents
Reagent for immunonephelometry and kit therefor Download PDFInfo
- Publication number
- JP2022074265A JP2022074265A JP2020184173A JP2020184173A JP2022074265A JP 2022074265 A JP2022074265 A JP 2022074265A JP 2020184173 A JP2020184173 A JP 2020184173A JP 2020184173 A JP2020184173 A JP 2020184173A JP 2022074265 A JP2022074265 A JP 2022074265A
- Authority
- JP
- Japan
- Prior art keywords
- measurement
- reagent
- measuring
- measured
- specific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 77
- 239000002245 particle Substances 0.000 claims abstract description 61
- 230000009870 specific binding Effects 0.000 claims abstract description 33
- 239000000126 substance Substances 0.000 claims abstract description 28
- 239000005018 casein Substances 0.000 claims abstract description 26
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000021240 caseins Nutrition 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 238000005259 measurement Methods 0.000 claims description 112
- 238000000034 method Methods 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 26
- 102100032752 C-reactive protein Human genes 0.000 claims description 23
- 238000004879 turbidimetry Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 238000009739 binding Methods 0.000 claims description 11
- 239000001913 cellulose Substances 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002131 composite material Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000004816 latex Substances 0.000 claims description 4
- 229920000126 latex Polymers 0.000 claims description 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 2
- 239000002082 metal nanoparticle Substances 0.000 claims description 2
- 239000000523 sample Substances 0.000 description 40
- 102000011632 Caseins Human genes 0.000 description 24
- 108010076119 Caseins Proteins 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 24
- 238000011088 calibration curve Methods 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000000691 measurement method Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000013068 control sample Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- -1 small molecule compound Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010029719 Nonspecific reaction Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- UTSXERRKRAEDOV-UHFFFAOYSA-N 3-[dimethyl-[3-(tetradecanoylamino)propyl]azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O UTSXERRKRAEDOV-UHFFFAOYSA-N 0.000 description 1
- GUQQBLRVXOUDTN-XOHPMCGNSA-N 3-[dimethyl-[3-[[(4r)-4-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 GUQQBLRVXOUDTN-XOHPMCGNSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 102100033899 Ankyrin repeat and SOCS box protein 14 Human genes 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101001016210 Bos taurus Dynein axonemal heavy chain 12 Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000925508 Homo sapiens Ankyrin repeat and SOCS box protein 14 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000023022 Pepsinogens Human genes 0.000 description 1
- 108010014475 Pepsinogens Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100023105 Sialin Human genes 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
本発明は、被検試料中の測定対象物の免疫比濁法測定用試薬及び測定用キットに関する。 The present invention relates to a reagent for measuring turbidimetry and a measurement kit of a measurement object in a test sample.
抗原と抗体の特異結合反応を利用した免疫学的測定方法として、酵素免疫測定法、蛍光酵素免疫測定法、免疫比濁法、免疫比ろう法、イムノクロマトグラフィー法等、多くの測定方法が知られている。 As an immunological measurement method using a specific binding reaction between an antigen and an antibody, many measurement methods such as an enzyme immunoassay method, a fluorescent enzyme immunoassay method, an immunoturbidimetric method, an immunopistosis fistula method, and an immunochromatography method are known. ing.
特に免疫比濁法は操作が簡便であり、測定の自動化が可能なことから広く普及している。免疫比濁法とは、測定対象物に特異的な抗体を感作した担体粒子を反応させ、特異結合反応により生成した複合凝集物の吸光度等を測定することで、測定対象物を検出する方法である。 In particular, the immunoturbidimetry method is widely used because it is easy to operate and the measurement can be automated. The immunoturbidimetric method is a method of detecting an object to be measured by reacting carrier particles sensitized with an antibody specific to the object to be measured and measuring the absorbance of the complex aggregate generated by the specific binding reaction. Is.
しかしながら、免疫学的測定方法は非特異反応により、測定対象物を正確に測定できない問題がある。非特異反応を防止するため、種々の蛋白質、界面活性剤及び塩類等を含有させた免疫測定用試薬が提案されている。例えば、標識配位子の非特異反応を防止するために90万ダルトン以上のカゼインを用いる方法(特許文献1)、蛋白質・ポリマー・塩類、あるいはそれらの組み合わせからなる非特異反応抑制剤を利用する方法(特許文献2)等が挙げられる。 However, the immunological measurement method has a problem that the measurement target cannot be accurately measured due to a non-specific reaction. In order to prevent non-specific reactions, immunoassay reagents containing various proteins, surfactants, salts and the like have been proposed. For example, a method using 900,000 daltons or more of casein to prevent a non-specific reaction of a labeled ligand (Patent Document 1), a non-specific reaction inhibitor consisting of a protein, a polymer, a salt, or a combination thereof is used. A method (Patent Document 2) and the like can be mentioned.
本発明は被検試料中の測定対象物を正確に測定することができる免疫比濁法測定用試薬及び測定用キットを提供することを課題とする。 An object of the present invention is to provide a reagent for measuring turbidimetry and a measurement kit capable of accurately measuring an object to be measured in a test sample.
本発明者らは、上記の課題を解決するために鋭意検討を重ねた結果、測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含む、測定対象物の免疫比濁法測定用試薬及び測定用キットによれば、上記課題を達成しうることを見出し、本発明を完成した。 As a result of diligent studies to solve the above problems, the present inventors have sensitized a carrier particle to a specific binding substance to the measurement target, and the immunological ratio of the measurement target containing casein or a salt thereof. The present invention has been completed by finding that the above-mentioned problems can be achieved by the turbidity method measuring reagent and the measuring kit.
本発明は、以下よりなる。
1.測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含む、測定対象物の免疫比濁法測定用試薬。
2.前記特異的結合物質が、測定対象物に特異的に結合する抗体又は抗原である、前項1に記載の免疫比濁法測定用試薬。
3.前記担体粒子が、セルロース粒子、ラテックス粒子、金属ナノ粒子、ゼラチン粒子のいずれかである、前項1又は2に記載の免疫比濁法測定用試薬。
4.前記測定用試薬が液状の場合に、前記担体粒子が0.10~0.25w/v%含まれ、前記カゼイン又はその塩が0.10~1.00w/v%含まれる、前項1~3のいずれかに記載の免疫比濁法測定用試薬。
5.さらに、糖類及び/又は界面活性剤を含む、前項1~4のいずれかに記載の免疫比濁法測定用試薬。
6.前記測定対象物が、C反応性蛋白質である、前項1~5のいずれかに記載の免疫比濁法測定用試薬。
7.前項1~6のいずれかに記載の免疫比濁法測定用試薬が測定用デバイスに塗布されており、測定に使用されるまで前記測定用試薬が乾燥状態に保持されていることを特徴とする、測定対象物の免疫比濁法による測定用キット。
8.測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含む、測定対象物の免疫比濁法測定用試薬が測定用デバイスに塗布されており、測定に使用されるまで前記測定用試薬が乾燥状態に保持されていることを特徴とする、測定対象物の免疫比濁法による測定用キット。
9.前項7又は8に記載の測定用キットに塗布された測定用試薬と被検試料を混合し、前記測定用試薬に含まれる前記担体粒子と被検試料中の測定対象物の特異結合反応により生成した複合凝集物を測定することによる測定対象物の測定方法。
10.以下の工程を含む、免疫比濁法による測定対象物の測定用キットの製造方法:
1)測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含む、測定対象物の免疫比濁法測定用試薬を測定用デバイスに塗布する工程;
2)前記測定用デバイスに塗布した測定用試薬を乾燥させる工程。
The present invention comprises the following.
1. 1. A reagent for measuring an immunoturbidimetric method of a measurement target, which comprises carrier particles sensitized to a specific binding substance to the measurement target and casein or a salt thereof.
2. 2. The reagent for measuring turbidimetry according to item 1 above, wherein the specific binding substance is an antibody or antigen that specifically binds to an object to be measured.
3. 3. The reagent for measuring an immunoturbidimetric method according to the above item 1 or 2, wherein the carrier particles are any one of cellulose particles, latex particles, metal nanoparticles, and gelatin particles.
4. 6. Reagent for measuring immunoturbidimetric method.
5. The reagent for measuring turbidimetry according to any one of the above items 1 to 4, further comprising a saccharide and / or a surfactant.
6. The reagent for measuring turbidimetry according to any one of the above items 1 to 5, wherein the measurement target is a C-reactive protein.
7. The reagent for measuring turbidimetry according to any one of the above items 1 to 6 is applied to a measuring device, and the measuring reagent is kept in a dry state until it is used for measurement. , A kit for measuring the object to be measured by the immunoturbidimetry method.
8. A reagent for measuring immunoturbidimetric method of the object to be measured, which contains carrier particles sensitized to a specific binding substance to the object to be measured and casein or a salt thereof, is applied to the device for measurement until it is used for measurement. A measurement kit by an immunoturbidimetric method of an object to be measured, characterized in that the measurement reagent is kept in a dry state.
9. The measurement reagent applied to the measurement kit according to the above item 7 or 8 is mixed with the test sample, and is generated by a specific binding reaction between the carrier particles contained in the measurement reagent and the measurement target in the test sample. A method for measuring an object to be measured by measuring the composite aggregate.
10. A method for manufacturing a kit for measuring an object to be measured by the immunoturbidimetry method, which comprises the following steps:
1) A step of applying a reagent for measuring an immunoturbidimetric method of a measurement target, which contains carrier particles sensitized to a specific binding substance to the measurement target and casein or a salt thereof, to the measurement device;
2) A step of drying the measurement reagent applied to the measurement device.
本発明の測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含む、測定対象物の免疫比濁法測定用試薬及び測定用キットによれば、当該担体粒子の非特異反応を効率的に抑制することができ、被検試料中の測定対象物を正確に測定することができる。 According to the immunoturbidimetric measurement reagent and measurement kit of the measurement target, which contains the carrier particles sensitized to the specific binding substance to the measurement target of the present invention and casein or a salt thereof, the carrier particles are not present. The peculiar reaction can be efficiently suppressed, and the measurement target in the test sample can be accurately measured.
以下、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail.
(1)測定用試薬
本発明の「測定用試薬」は、測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含有することを特徴とするものである。
(1) Reagent for measurement The "reagent for measurement" of the present invention is characterized by containing carrier particles sensitized to a specific binding substance to an object to be measured, and casein or a salt thereof.
本明細書において「担体粒子」とは、免疫比濁法による測定に利用可能な担体粒子であって、測定対象物に対する特異的結合物質を感作することができれば、特に限定されない。担体粒子としては、例えばセルロース粒子、ラテックス粒子、金ナノ粒子、ゼラチン粒子、リポソーム、マイクロカプセル、又は赤血球等の粒子等が挙げられ、セルロース粒子、ラテックス粒子、金ナノ粒子、ゼラチン粒子が好ましく、特にセルロース粒子が好ましい。 As used herein, the "carrier particles" are carrier particles that can be used for measurement by the turbidimetry method, and are not particularly limited as long as they can sensitize a specific binding substance to the object to be measured. Examples of the carrier particles include cellulose particles, latex particles, gold nanoparticles, gelatin particles, liposomes, microcapsules, particles such as erythrocytes, and the like, preferably cellulose particles, latex particles, gold nanoparticles, gelatin particles, and the like. Cellulous particles are preferred.
免疫比濁法による測定において、担体粒子の平均粒子径は特に限定されない。測定対象物に対する特異的結合物質を感作した担体粒子と、被検試料中の測定対象物との特異結合反応により生成した複合凝集物の生成しやすさ、及び生成した複合体凝集物の測定の容易さ等の理由により、担体粒子の平均粒子径が、50nm~1000nmが好ましく、特に100nm ~400nmが好ましい。担体粒子は、その粒径、又は形状等が異なる2種類以上の担体粒子を使用してもよい。 In the measurement by the turbidimetry method, the average particle size of the carrier particles is not particularly limited. Ease of forming composite aggregates produced by the specific binding reaction between the carrier particles sensitized to the specific binding substance to the measurement target and the measurement target in the test sample, and the measurement of the produced complex aggregates. The average particle size of the carrier particles is preferably 50 nm to 1000 nm, and particularly preferably 100 nm to 400 nm for reasons such as ease of use. As the carrier particles, two or more types of carrier particles having different particle sizes, shapes, and the like may be used.
本明細書において「特異的結合物質」とは、測定対象物に対して特異結合反応を生じる物質であればよく、特に限定されない。抗原抗体反応に利用できる物質が好ましく、特に測定対象物に特異的に結合する抗体又は抗原が好ましい。測定対象物が抗原の場合には、その抗原に対応する抗体が挙げられ、例えば、モノクローナル抗体、ポリクローナル抗体、キメラ抗体、ヒト抗体又は一本鎖抗体(scFv)、及びこれらの抗体の断片(Fab、F(ab')2)、Fab'、Fv、sFv、dsFv等)等から適宜選択して使用することができる。また、抗体又は抗体断片に、タンパク質又は低分子化合物を結合させて誘導体を使用することもできる。抗体の由来については特に限定されないが、例えば哺乳動物(マウス、ウサギ、ラット、ヒツジ、ヤギ、若しくはウマ等)、または鳥類(ニワトリ、ウズラ、キジ、ダチョウ、若しくはアヒル等)等が挙げられる。測定対象物が抗体の場合は、その抗体に対する抗原であれば良く、例えば、上記例示した抗体に対する抗原を抗原として使用すれば良い。 As used herein, the “specific binding substance” is not particularly limited as long as it is a substance that causes a specific binding reaction with respect to the object to be measured. A substance that can be used for an antigen-antibody reaction is preferable, and an antibody or an antigen that specifically binds to an object to be measured is particularly preferable. When the object to be measured is an antigen, an antibody corresponding to the antigen can be mentioned, for example, a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a human antibody or a single-stranded antibody (scFv), and a fragment (Fab) of these antibodies. , F (ab') 2), Fab', Fv, sFv, dsFv, etc.) can be appropriately selected and used. In addition, a derivative can be used by binding a protein or a small molecule compound to an antibody or an antibody fragment. The origin of the antibody is not particularly limited, and examples thereof include mammals (mouse, rabbit, rat, sheep, goat, horse, etc.), birds (chicken, quail, pheasant, ostrich, duck, etc.) and the like. When the object to be measured is an antibody, it may be an antigen against the antibody, and for example, the antigen against the above-exemplified antibody may be used as the antigen.
本発明における「カゼイン又はその塩」は、担体粒子の非特異反応を抑制するためのブロッキング剤として使用される。例えばαs-カゼイン、β-カゼイン及びκ-カゼイン等を挙げることができ、また、これらのカゼインに水酸化ナトリウムを付加してもよい。カゼイン又はその塩としては、カゼイン Naであることが好ましい。 The "casein or a salt thereof" in the present invention is used as a blocking agent for suppressing a non-specific reaction of carrier particles. For example, αs-casein, β-casein, κ-casein and the like can be mentioned, and sodium hydroxide may be added to these caseins. The casein or a salt thereof is preferably casein Na.
本発明の測定用試薬は、さらに糖類、界面活性剤等の添加物を加えてもよい。糖類としては、例えばスクロース、ソルビトール、マンニトール、トレハロース、ラクトース、キシリトール、ガラクトース、アロース、グルコース、アルトロース等が挙げられ、特にスクロース、ソルビトール、マンニトールが好ましい。界面活性剤としては、両性界面活性剤、非イオン性界面活性剤が挙げられ、例えば、CHAPS、CHAPSO、ASB-14、C7Bz0、Tween20、Briji35、I GEPAL CA-630、ジギトニン等が挙げられ、特にCHAPS、Briji35が好ましい。 Additives such as saccharides and surfactants may be further added to the measurement reagent of the present invention. Examples of the saccharide include sucrose, sorbitol, mannitol, trehalose, lactose, xylitol, galactose, allose, glucose, altrose and the like, and sucrose, sorbitol and mannitol are particularly preferable. Examples of the surfactant include amphoteric surfactants and nonionic surfactants, and examples thereof include CHAPS, CHAPSO, ASB-14, C7Bz0, Tween20, Briji35, I GEPAL CA-630, and digitonin. CHAPS and Briji35 are preferred.
(2)測定用試薬の調製方法
本発明の測定用試薬において、測定対象物に対する特異的結合物質を担体粒子への感作は特に限定されないが、例えば以下のようにして調製することができる。担体粒子に抗体等の特異的結合物質を加え水系溶媒中で撹拌後、遠心分離により測定対象物に対する特異的結合物質を感作した担体粒子を洗浄することで当該担体粒子を調製できる。
(2) Method for Preparing Reagent for Measurement In the reagent for measurement of the present invention, the sensitization to the carrier particles of the specific binding substance to the object to be measured is not particularly limited, but can be prepared, for example, as follows. The carrier particles can be prepared by adding a specific binding substance such as an antibody to the carrier particles, stirring the mixture in an aqueous solvent, and then washing the carrier particles sensitized with the specific binding substance to the object to be measured by centrifugation.
当該結合物質が感作した担体粒子に各種の水系溶媒を加え、カゼイン又はその塩を添加することで本発明の測定用試薬を調製することができる。さらに上記添加物、特異的結合物質を加えてもよい。水系溶媒としては、例えば精製水、生理食塩水、Tris緩衝液、リン酸緩衝液等が挙げられ、水系溶媒のpHについては例えばpH 5~10が一般的である。特異的結合物質は担体粒子に感作させるだけでなく、測定対象物に対する特異的結合物質を感作した担体粒子と、被検試料中の測定対象物の特異結合反応に対する感度を調整するために測定用試薬に加えることができる。 The reagent for measurement of the present invention can be prepared by adding various aqueous solvents to the carrier particles sensitized by the binding substance and adding casein or a salt thereof. Further, the above additives and specific binding substances may be added. Examples of the aqueous solvent include purified water, physiological saline, Tris buffer, phosphate buffer and the like, and the pH of the aqueous solvent is generally pH 5 to 10, for example. The specific binding substance not only sensitizes the carrier particles, but also adjusts the sensitivity of the carrier particles sensitized to the specific binding substance to the measurement target and the specific binding reaction of the measurement target in the test sample. It can be added to the measuring reagent.
上記の方法で調製された液状の本発明の測定用試薬には、測定対象物に対する特異的結合物質を感作した担体粒子が0.10~0.50w/v%、好ましくは0.15~0.25w/v%含まれ、及びカゼイン又はその塩が0.05~5.00w/v%、好ましくは0.10~1.00w/v%含まれる。 The liquid reagent for measurement of the present invention prepared by the above method contains 0.10 to 0.50 w / v%, preferably 0.15 to 0.25 w / v% of carrier particles sensitized to a specific binding substance to the object to be measured. It is contained and contains 0.05-5.00w / v%, preferably 0.10-1.00w / v% of casein or a salt thereof.
(3)測定用キット
本発明は、測定対象物の免疫比濁法による「測定用キット」も含まれる。当該キットは、本発明の測定用試薬が測定用デバイスに塗布、乾燥されており、測定に使用されるまで当該測定用試薬が乾燥状態に保持されていることを特徴とする。
(3) Measurement kit The present invention also includes a "measurement kit" by the immunoturbidimetric method of the object to be measured. The kit is characterized in that the measuring reagent of the present invention is applied to a measuring device and dried, and the measuring reagent is kept in a dry state until it is used for measurement.
本発明の測定用キットにおいて「測定用デバイス」とは、少なくとも被検試料を供給するための試料供給部と、測定対象物に対する特異的結合物質を感作した担体粒子を含有する本発明の測定用試薬が塗布されている反応部を含む。さらに試料供給部に供給された被検試料を反応部まで導入するための経路を構成要素として含むことが好ましい。当該反応部は、本発明の測定用試薬を塗布する部分として上部と下部があることが好ましく、当該測定用試薬と被検試料を混合しうる形状であればよく、例えば凹状であることが好ましい。 In the measurement kit of the present invention, the "measurement device" is the measurement of the present invention containing at least a sample supply unit for supplying a test sample and carrier particles sensitized to a specific binding substance to the object to be measured. Includes the reaction part to which the reagent is applied. Further, it is preferable to include a route for introducing the test sample supplied to the sample supply unit to the reaction unit as a component. The reaction portion preferably has an upper portion and a lower portion as a portion to which the measurement reagent of the present invention is applied, and may have a shape that allows the measurement reagent and the test sample to be mixed, and is preferably concave, for example. ..
(4)測定用キットの製造方法
本発明は、免疫比濁法による測定対象物の「測定用キットの製造方法」も含まれる。
本発明の測定用キットの製造方法は、本発明の測定用試薬を測定用デバイスに塗布する工程と本発明の測定用試薬を乾燥させる工程を含むことを特徴とする。
(4) Method for manufacturing a measurement kit The present invention also includes a "method for manufacturing a measurement kit" for a measurement object by the turbidimetry method.
The method for producing a measurement kit of the present invention is characterized by comprising a step of applying the measurement reagent of the present invention to a measurement device and a step of drying the measurement reagent of the present invention.
本発明の「測定用キットの製造方法」において、本発明の測定用試薬を測定用デバイスの反応部に塗布することが好ましく、本発明の測定用試薬を液状状態で測定用デバイスに塗布した後に乾燥状態にさせてもよいし、乾燥状態の本発明の測定用試薬を測定用デバイスに塗布してもよい。本発明の測定用試薬を乾燥する方法としては、例えば、自然乾燥や凍結乾燥等が挙げられる。 In the "method for manufacturing a measurement kit" of the present invention, it is preferable to apply the measurement reagent of the present invention to the reaction part of the measurement device, and after the measurement reagent of the present invention is applied to the measurement device in a liquid state. It may be allowed to be in a dry state, or the measurement reagent of the present invention in a dry state may be applied to the measurement device. Examples of the method for drying the measurement reagent of the present invention include natural drying and freeze-drying.
(5)測定方法
本発明は、「測定対象物の測定方法」も含まれる。本発明の測定方法は、本発明の測定用キットに塗布された測定用試薬と被検試料を混合し、当該測定用試薬に含まれる、測定対象物に対する特異的結合物質を感作した担体粒子と、被検試料中の測定対象物の特異結合反応により生成した複合凝集物を測定することで測定対象物を測定する方法である。
(5) Measurement Method The present invention also includes a "measurement method for an object to be measured". In the measuring method of the present invention, a measuring reagent applied to the measuring kit of the present invention and a test sample are mixed, and carrier particles contained in the measuring reagent and sensitized to a specific binding substance to a measurement object are sensitized. This is a method of measuring an object to be measured by measuring a complex aggregate generated by a specific binding reaction of the object to be measured in the test sample.
以下、本発明の測定方法を具体的に説明する。
1)被検試料を本発明の測定用キットに含まれる測定用デバイスの試料供給部に供給すると、被検試料が、例えば測定用デバイスの経路を通って反応部に移動する。反応部には本発明の測定用試薬が塗布されているため、被検試料が本発明の測定用試薬を乾燥状態から溶解することで本発明の測定用試薬と被検試料が混合する。本発明の測定用試薬は反応部の上部のみに塗布しても、下部のみに塗布しても、また両方に塗布してもよい。
2)本発明の測定用試薬と被検試料が混合することで、本発明の測定用試薬に含まれる当該担体粒子と被検試料中の測定対象物の特異結合反応により複合凝集物が生成する。
3)前記生成した複合凝集物を含む溶液に光を照射し吸光度を測定することで、被検試料中に含まれている測定対象物を検出することができる。
Hereinafter, the measuring method of the present invention will be specifically described.
1) When the test sample is supplied to the sample supply unit of the measurement device included in the measurement kit of the present invention, the test sample moves to the reaction unit, for example, through the path of the measurement device. Since the measurement reagent of the present invention is applied to the reaction section, the measurement reagent of the present invention and the test sample are mixed by dissolving the measurement reagent of the present invention from a dry state. The reagent for measurement of the present invention may be applied only to the upper part of the reaction part, only to the lower part, or may be applied to both.
2) By mixing the measurement reagent of the present invention and the test sample, a composite aggregate is generated by a specific binding reaction between the carrier particles contained in the measurement reagent of the present invention and the measurement target in the test sample. ..
3) By irradiating the solution containing the generated complex aggregate with light and measuring the absorbance, the object to be measured contained in the test sample can be detected.
本発明の測定方法において、反応部で本発明の測定用試薬と被検試料を反応させる温度は、例えば0~50℃であり、4~40℃が好ましい。前記生成した複合凝集物を含む溶液に光を照射するときは反応部に光を照射することが好ましく、光を照射するには、例えば分光光度計等により照射することができる。 In the measuring method of the present invention, the temperature at which the measuring reagent of the present invention and the test sample are reacted in the reaction section is, for example, 0 to 50 ° C, preferably 4 to 40 ° C. When irradiating the solution containing the generated composite aggregate with light, it is preferable to irradiate the reaction portion with light, and to irradiate the light, for example, a spectrophotometer or the like can be used.
本発明の測定方法に供するための「被検試料」は、生体から取得した検体そのものであってもよく、検体から調製されたものであってもよい。例えば、被検試料は、血液試料、体液、尿試料等が挙げられる。血液試料は、例えば、全血、血清、血漿等が挙げられる。 The "test sample" to be used for the measurement method of the present invention may be a sample itself obtained from a living body or may be prepared from a sample. For example, the test sample includes a blood sample, a body fluid, a urine sample and the like. Examples of the blood sample include whole blood, serum, plasma and the like.
本明細書において「測定対象物」とは、一般的な臨床検査等における検査対象物が挙げられ、具体的には、血液、尿、唾液、分泌液等に含まれる各種成分や、組織、便等の固形物からの抽出液等に含まれる各種成分等が挙げられる。測定対象物の例として、具体的にはCRP、アルブミン、AST、ALT、γGTP、ヘモグロビン、ヘモグロビンA1c、ミオグロビン、トランスフェリン、ラクトフェリン、シスタチンC、フェリチン、α-フェトプロテイン、癌胎児性抗原、CA19-9、前立腺特異抗原、繊維素分解産物(FDP)、ペプシノーゲンIおよびII、コラーゲンなどの蛋白質;高比重リポ蛋白質、低比重リポ蛋白質、超低比重リポ蛋白質などの脂質蛋白質;デオキシリボ核酸、リボ核酸などの核酸;アルカリ性ホスファターゼ、乳酸脱水素酵素、リパーゼ、アミラーゼなどの酵素;IgG、IgM、IgA、IgD、IgEなどの免疫グロブリン;B型肝炎ウイルス、C型肝炎ウイルス、ヒト免疫不全ウイルス、ヘリコバクターピロリ;性ホルモンなどのホルモン等が挙げられる。特にCRPが挙げられる。CRPとは、肺炎球菌のC多糖体と沈降反応を示す血清タンパク質であり、通常血清中に微量に存在する。血中CRP濃度の上昇は、各種炎症性疾患が生ずると急激に増加する。このため、CRPは炎症マーカーとして、感染症、炎症等の疾患の診断のために測定される。 In the present specification, the "measurement object" includes an object to be inspected in a general clinical examination or the like, and specifically, various components contained in blood, urine, saliva, secretions, etc., tissues, feces, etc. Examples thereof include various components contained in an extract or the like from a solid substance such as. Specific examples of objects to be measured include CRP, albumin, AST, ALT, γGTP, hemoglobin, hemoglobin A1c, myoglobin, transferase, lactoferrin, cystatin C, ferritin, α-fetoprotein, cancer fetal antigen, CA19-9, Proteins such as prostate-specific antigens, fibrinolytic products (FDPs), pepsinogens I and II, collagen; lipid proteins such as high specific gravity lipoproteins, low specific gravity lipoproteins, and ultralow specific gravity lipoproteins; nucleic acids such as deoxyribonucleic acid and ribonucleic acid. Enzymes such as alkaline phosphatase, lactic acid dehydrogenase, lipase, amylase; immunoglobulins such as IgG, IgM, IgA, IgD, IgE; hepatitis B virus, hepatitis C virus, human immunodeficiency virus, helicobacter pyrori; sex hormone Examples include hormones such as. Especially CRP. CRP is a serum protein that exhibits a precipitation reaction with C-polysaccharide of Streptococcus pneumoniae, and is usually present in a trace amount in serum. The increase in blood CRP concentration increases sharply when various inflammatory diseases occur. Therefore, CRP is measured as an inflammation marker for the diagnosis of diseases such as infectious diseases and inflammation.
以下、実施例及び比較例により発明を具体的に詳述するが、本発明はこれらの実施例等により限定されるものではない。 Hereinafter, the invention will be described in detail with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples and the like.
(実施例1)カゼイン Naの非特異反応抑制評価及び正確性・同時再現性の評価
実施例1では、本発明の測定用試薬についてカゼイン Naの非特異反応抑制評価及び正確性・同時再現性の評価を確認した。
(Example 1) Evaluation of non-specific reaction suppression of casein Na and evaluation of accuracy / simultaneous reproducibility In Example 1, evaluation of non-specific reaction suppression of casein Na and accuracy / simultaneous reproducibility of the measurement reagent of the present invention. Confirmed the evaluation.
1)抗CRP抗体感作セルロース粒子の調製
セルロース粒子への抗CRP抗体の感作は以下の様に行った。平均粒径330nmのセルロース粒子(NanoAct(登録商標)、旭化成せんい株式会社販売)を0.1w/v%と抗CRP抗体が100μg/mlの濃度になるように緩衝溶液中で撹拌後、遠心分離により抗CRP抗体感作セルロース粒子を洗浄し調製した。
1) Preparation of anti-CRP antibody sensitized cellulose particles Sensitization of anti-CRP antibody to cellulose particles was performed as follows. Cellulose particles with an average particle size of 330 nm (NanoAct®, sold by Asahi Kasei Fibers Co., Ltd.) are stirred in a buffer solution to a concentration of 0.1 w / v% and anti-CRP antibody at a concentration of 100 μg / ml, and then centrifuged. Anti-CRP antibody sensitized cellulose particles were washed and prepared.
2)測定用試薬の調製
上記1)で得られた抗CRP抗体感作セルロース粒子に精製水、抗CRP抗体、カゼイン Na(Casein Na)、糖類、界面活性剤を加え測定用試薬を調製した。比較例としてカゼイン Naの替わりにBSA(ウシ血清アルブミン)又はスキムミルクを加えた測定用試薬を調製した。各測定用試薬の試薬組成を表1にまとめた。
2) Preparation of reagent for measurement Purified water, anti-CRP antibody, casein Na, saccharide, and surfactant were added to the anti-CRP antibody-sensitized cellulose particles obtained in 1) above to prepare a reagent for measurement. As a comparative example, a measurement reagent was prepared by adding BSA (bovine serum albumin) or skim milk instead of casein Na. The reagent composition of each measurement reagent is summarized in Table 1.
3)測定用キットの作製
測定用デバイスの反応部の上部及び下部に、上記2)で作製した測定用試薬0.45μL、0.5μLを各々塗布し室温にて自然乾燥させ測定用キットを作製した。
3) Preparation of measurement kit To the upper and lower parts of the reaction part of the measurement device, 0.45 μL and 0.5 μL of the measurement reagents prepared in 2) above were applied and air-dried at room temperature to prepare a measurement kit.
4)CRP管理検体の調製
rCRP(オリエンタル酵母工業株式会社販売)をCRPフリー血清(オリエンタル酵母工業株式会社販売)で希釈してCRP管理検体0.4mg/dL、0.8mg/dL、1.6mg/dL、3.0mg/dLとした。CRPフリー血清及び上記調製したCRP管理検体を測定用デバイスの試料供給部に導入して測定用試薬と混合した。
4) Preparation of CRP controlled sample
rCRP (sold by Oriental Yeast Co., Ltd.) was diluted with CRP-free serum (sold by Oriental Yeast Co., Ltd.) to obtain CRP controlled samples 0.4 mg / dL, 0.8 mg / dL, 1.6 mg / dL, and 3.0 mg / dL. The CRP-free serum and the prepared CRP-controlled sample were introduced into the sample supply section of the measurement device and mixed with the measurement reagent.
5)吸光度の測定
CRPフリー血清及びCRP管理検体を測定用デバイスに導入して測定用試薬と混合させた後、7分間、37℃で反応させ、測定用試薬が塗布された反応部に対して波長主630nm/副810nmで測光し反応後の吸光度を測定した。CRPフリー血清、CRP管理検体についてそれぞれN=3で測定した。
5) Measurement of absorbance
CRP-free serum and CRP-controlled sample are introduced into the measurement device, mixed with the measurement reagent, and then reacted at 37 ° C for 7 minutes. Photometry was performed at 810 nm and the absorbance after the reaction was measured. CRP-free serum and CRP-controlled sample were measured at N = 3, respectively.
6)検量線の作成
上記4)で得られたCRPフリー血清、CRP既知濃度(0.4、0.8、1.6、3.0mg/dL)のCRP管理検体について、平均吸光度から検量線を作成した。
6) Preparation of calibration curve A calibration curve was prepared from the average absorbance of the CRP-free serum obtained in 4) above and the CRP-controlled sample having a known CRP concentration (0.4, 0.8, 1.6, 3.0 mg / dL).
その結果、比較例1(BSA)及び比較例2(スキムミルク)では、非特異反応が確認され、理想的な検量線が得られなかった。抗CRP抗体感作セルロース粒子に添加するタンパク質をカゼイン Naとし、糖類、界面活性剤の種類を変更した実施例1-1~1-4では、非特異反応は生じずにCRP 0.0-3.0mg/dLまで濃度依存的な反応がみられ、理想的な検量線を引くことができた。 As a result, in Comparative Example 1 (BSA) and Comparative Example 2 (skimmed milk), a non-specific reaction was confirmed, and an ideal calibration curve could not be obtained. Anti-CRP antibody In Examples 1-1 to 1-4 in which the protein added to the sensitized cellulose particles was casein Na and the types of saccharides and surfactants were changed, no non-specific reaction occurred and CRP 0.0-3.0 mg / A concentration-dependent reaction was observed up to dL, and an ideal calibration curve could be drawn.
7)正確性、同時再現性の評価
被検試料としてコントロール検体1(既知濃度0.41mg/dl)、コントロール検体2(既知濃度1.04mg/dl)を用いて、上記5)と同様の手順で2濃度のコントロール検体をN=5で測定し、得られた吸光度を上記作成した検量線(実施例1-1~1-4)から濃度換算し、正確性、同時再現性を評価した。
7) Evaluation of accuracy and simultaneous reproducibility Using control sample 1 (known concentration 0.41 mg / dl) and control sample 2 (known concentration 1.04 mg / dl) as test samples, 2 in the same procedure as 5) above. The concentration control sample was measured at N = 5, and the obtained absorbance was converted into a concentration from the calibration curve (Examples 1-1 to 1-4) prepared above, and the accuracy and simultaneous reproducibility were evaluated.
<正確性の評価方法>
正確性については、上記2濃度のCRPコントロール検体をN=5で測定した平均値と既知濃度を比較し、既知濃度差を算出した。なお、既知濃度±0.2mg/dL以内が正確性が高いことを意味する。
<同時再現性の評価方法>
同時再現性については、上記2濃度のCRPコントロール検体をN=5で測定し、その標準偏差(SD)を算出した。なお、標準偏差0.1mg/dL以下が同時再現性が高いことを意味する。
<Accuracy evaluation method>
For accuracy, the mean value measured at N = 5 and the known concentration were compared with the above two concentrations of CRP control sample, and the known concentration difference was calculated. It means that the accuracy is high when the known concentration is within ± 0.2 mg / dL.
<Evaluation method of simultaneous reproducibility>
For simultaneous reproducibility, the above two concentrations of CRP control sample were measured at N = 5, and the standard deviation (SD) was calculated. A standard deviation of 0.1 mg / dL or less means that the simultaneous reproducibility is high.
上記2濃度のコントロール検体を測定した正確性および同時再現性の測定結果を表2に示した。比較例1(BSA)、比較例2(スキムミルク)は非特異反応が生じ、正確性・同時再現性について正しく評価できなかった。カゼイン Naを添加した実施例1-1~1-4においては2濃度のコントロール検体ともに既知濃度差±0.2mg/dL以内、標準偏差0.1 mg/dL以下となり、正確性・同時再現性の規格を満たした。 Table 2 shows the measurement results of the accuracy and simultaneous reproducibility of the control samples having the above two concentrations. In Comparative Example 1 (BSA) and Comparative Example 2 (skimmed milk), a non-specific reaction occurred, and the accuracy and simultaneous reproducibility could not be evaluated correctly. In Examples 1-1 to 1-4 to which casein Na was added, the known concentration difference was within ± 0.2 mg / dL and the standard deviation was 0.1 mg / dL or less for both of the two concentration control samples. Satisfied.
(実施例2)カゼイン Naの至適濃度の確認
実施例2では、本発明の測定用試薬についてカゼイン Naの至適濃度を確認した。
(Example 2) Confirmation of the optimum concentration of casein Na In Example 2, the optimum concentration of casein Na was confirmed for the measuring reagent of the present invention.
実施例2では、抗CRP抗体感作セルロース粒子を0.2w/v%、スクロースを0.5w/v%、CHAPSを0.25w/v%、抗CRP抗体100μg/mlに特定し、カゼイン Na(Casein Na)を0.1w/v%、0.2w/v%、0.4w/v%、0.6w/v%、0.8w/v%、1.00w/v%となるように測定用試薬を調製した(表3)。測定用試薬の調製方法は実施例1に従った。 In Example 2, anti-CRP antibody-sensitized cellulose particles were specified as 0.2 w / v%, sucrose as 0.5 w / v%, CHAPS as 0.25 w / v%, and anti-CRP antibody as 100 μg / ml. ) Was 0.1w / v%, 0.2w / v%, 0.4w / v%, 0.6w / v%, 0.8w / v%, 1.00w / v%. ). The method for preparing the reagent for measurement was according to Example 1.
1)検量線の作成
表3で示した測定用試薬について上記実施例1と同様の手順でCRPフリー血清、及びCRP管理検体の各被検試料の平均吸光度から検量線を作成した。カゼイン Na全ての濃度においてCRP 0.0-3.0mg/dLで濃度依存的な反応がみられ、理想的な検量線を得る事ができた。また、上述の検量線から濃度換算した平均値(測定値)とCRPフリー血清、CRP既知濃度(0.4、0.8、1.6、3.0mg/dL)のCRP管理検体との関係をグラフで示した(図1)。濃度換算した平均値(測定値)が既知濃度に近い値であった。
1) Preparation of calibration curve For the measurement reagents shown in Table 3, a calibration curve was prepared from the average absorbance of each test sample of CRP-free serum and CRP-controlled sample by the same procedure as in Example 1 above. A concentration-dependent reaction was observed at all concentrations of casein Na at CRP 0.0-3.0 mg / dL, and an ideal calibration curve could be obtained. In addition, the relationship between the mean value (measured value) converted from the above calibration curve and the CRP-controlled sample of CRP-free serum and CRP known concentration (0.4, 0.8, 1.6, 3.0 mg / dL) is shown in a graph (Fig.). 1). The average value (measured value) converted to concentration was close to the known concentration.
以上詳述したように、本発明の免疫比濁法測定用試薬及び測定用キットによれば、非特異反応を効率的に抑制することができることから理想的な検量線を引くことができ、かつ被検試料中の測定対象物を正確に測定することができる。 As described in detail above, according to the reagent for measuring turbidimetry and the measuring kit of the present invention, an ideal calibration curve can be drawn because non-specific reactions can be efficiently suppressed. It is possible to accurately measure the object to be measured in the test sample.
Claims (10)
1)測定対象物に対する特異的結合物質を感作した担体粒子と、カゼイン又はその塩を含む、測定対象物の免疫比濁法測定用試薬を測定用デバイスに塗布する工程;
2)前記測定用デバイスに塗布した測定用試薬を乾燥させる工程。 A method for manufacturing a kit for measuring an object to be measured by the immunoturbidimetry method, which comprises the following steps:
1) A step of applying a reagent for measuring an immunoturbidimetric method of a measurement target, which contains carrier particles sensitized to a specific binding substance to the measurement target and casein or a salt thereof, to the measurement device;
2) A step of drying the measurement reagent applied to the measurement device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020184173A JP2022074265A (en) | 2020-11-04 | 2020-11-04 | Reagent for immunonephelometry and kit therefor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020184173A JP2022074265A (en) | 2020-11-04 | 2020-11-04 | Reagent for immunonephelometry and kit therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022074265A true JP2022074265A (en) | 2022-05-18 |
Family
ID=81606136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020184173A Pending JP2022074265A (en) | 2020-11-04 | 2020-11-04 | Reagent for immunonephelometry and kit therefor |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2022074265A (en) |
-
2020
- 2020-11-04 JP JP2020184173A patent/JP2022074265A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5735615B2 (en) | Method for enhancing sensitivity in immunological measurement and reagent therefor | |
JP5364310B2 (en) | Method for stabilizing microparticles to which reactive substances are bound, and reagent containing the microparticles | |
JP6910699B2 (en) | Lectin target molecule capture method | |
JP2022033286A (en) | Hemoglobin measurement reagent, measurement kit, and measurement method | |
JP5786188B2 (en) | Reagent for measuring C-reactive protein in sample, measuring method, and method for expanding measuring range | |
WO2010047163A1 (en) | Method and reagent kit for immunological measurement | |
JP2005283250A (en) | Measuring method of gold colloid agglutination reaction | |
JP2022074265A (en) | Reagent for immunonephelometry and kit therefor | |
KR20100095422A (en) | Method and kit for measurement of acrolein adduct in sample utilizing agglutination reaction of immunological microparticle | |
JP5085736B2 (en) | Method for measuring complex and kit used therefor | |
JP4454885B2 (en) | Immunoassay method and reagent therefor | |
JP4982107B2 (en) | Method of measuring specimen using agglutination reaction of immunological microparticles and kit for measurement | |
JP5586232B2 (en) | Method and kit for immunological measurement of specimen using agglutination reaction of microparticles | |
JP5177677B2 (en) | Method for measuring antigen and antibody against the antigen, and measuring reagent used therefor | |
JPH0727764A (en) | Antibody for immunological measurement blocking fc part, reagent for immunological measurement containing said antibody, immunological measuring method using said reagent for immunological measurement and block reagent blocking fc part | |
JP2009031252A (en) | Method of measuring substance, and kit to be used for the same | |
JP2654932B2 (en) | C-reactive protein measurement reagent | |
JP2000146974A (en) | Immunoassay | |
JP2012078161A (en) | Measuring method of measuring target substance in sample, measuring reagent and method for improving measurement value difference | |
JPH06167493A (en) | Measuring method for immunity | |
CN117664672A (en) | Solution for improving matrix effect and application thereof | |
JP2024046503A (en) | Method, calibrator and conjugate for measuring alkaline phosphatase activity contained in extracellular vesicles | |
JP3783084B2 (en) | Reduced denatured serum albumin, production method thereof, treponema antigen sensitization material, and measurement method of treponema antibody | |
JP4753740B2 (en) | Reactivity enhancers and their applications | |
JPH1123578A (en) | Measuring method for aldolase isozyme and standard solution for measuring alsolase isozyme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230928 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240501 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240514 |